sildenafil-citrate and Dilatation--Pathologic

sildenafil-citrate has been researched along with Dilatation--Pathologic* in 2 studies

Trials

1 trial(s) available for sildenafil-citrate and Dilatation--Pathologic

ArticleYear
Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
    American journal of hypertension, 2004, Volume: 17, Issue:11 Pt 1

    Endothelial dysfunction is a key early event in the process of atherosclerosis and a risk factor for cardiovascular events. Sildenafil, an effective oral treatment for patients with erectile dysfunction, inhibits cGMP degradation by specific type 5 phosphodiesterase (PDE) inhibition. Sildenafil has been shown to improve vascular function, however, the effect of type 5 PDE inhibition on acute smoking-induced endothelial dysfunction is unknown.. We studied the effect of 50 mg of sildenafil on acute smoking-induced endothelial dysfunction in 14 male smokers according to a randomized, placebo-controlled, cross-over design. Endothelial function was evaluated with flow-mediated dilatation (FMD) of the brachial artery using high-resolution ultrasonography.. Sildenafil abolishes the decrease in FMD of the brachial artery that is induced acutely by smoking (placebo/smoking session: from 4.56% +/- 0.60% to 2.80% +/- 0.43%, sildenafil/smoking session: from 3.83% +/- 0.64% to 4.33% +/- 0.47%, ie, improvement of 51%, P < .05). This was associated with no reversal effect of sildenafil on smoking-induced decrease in resting brachial artery diameter and with a partial reversal of the smoking-induced decrease in hyperemic brachial artery diameter (placebo/smoking session: from 4.68 +/- 0.13 mm to 4.53 +/- 0.15 mm, sildenafil/smoking session: from 4.72 +/- 0.12 mm to 4.64 +/- 0.13 mm, ie, improvement of 1.5%, P < .005).. The present study shows, for the first time, that type 5 PDE inhibition with sildenafil abrogates the smoking-induced acute decrease in FMD of the brachial artery. These findings may have clinical implications given the detrimental consequences of smoking and the strategic role of normal endothelial function.

    Topics: Acute Disease; Adult; Cross-Over Studies; Dilatation, Pathologic; Double-Blind Method; Endothelium, Vascular; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Smoking; Sulfones; Vascular Diseases; Vasodilation

2004

Other Studies

1 other study(ies) available for sildenafil-citrate and Dilatation--Pathologic

ArticleYear
Should right ventricle dilatation during exercise have clinical implications in patients with chronic thromboembolic pulmonary hypertension? Case report.
    Cardiovascular ultrasound, 2007, Dec-27, Volume: 5

    We describe the case of a 30-year-old female patient with chronic thromboembolic pulmonary hypertension that has an excellent functional capacity under treatment with sildenafil. She did an exercise stress echocardiography that revealed marked right ventricular dilatation during exercise. This information was used for clinical decision and the authors discuss the potential utility of this echocardiographyc sign.

    Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Dilatation, Pathologic; Echocardiography, Doppler; Exercise Test; Female; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thromboembolism; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right

2007